Rockefeller Capital Management’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
Other funds holding TSHA
SL
Rockefeller Capital Management's TSHA Position: Q3 2026 in Review
Rockefeller Capital Management held its Taysha Gene Therapies (TSHA) position steady in Q3 2026 at 5,000 shares worth $24.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3821.
Rockefeller Capital Management first reported a position in TSHA in Q3 2025 and has held it in 5 quarters since. The position peaked at $34K in Q2 2026. 135 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.
- Rockefeller Capital Management held 5,000 shares of Taysha Gene Therapies worth $24.4K as of Q3 2026.
- Rockefeller Capital Management left its Taysha Gene Therapies share count unchanged in Q3 2026.
- Taysha Gene Therapies made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3821 holding.
- Rockefeller Capital Management first reported a position in Taysha Gene Therapies in Q3 2025 and has held it in 5 quarters since.
- Rockefeller Capital Management's Taysha Gene Therapies position peaked at $34K in Q2 2026.
- 135 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.